1-19 of 19
William E. Pierceall
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Multiomic Single-Cell Atlas of Human Myelopoiesis Reveals Cellular and Molecular Drivers of Immunomodulatory Drug-Induced Neutropenia

Christina Simoglou Karali, Simone Riva, Sally-Ann Clark, Sean Wen, Nikolaos Sousos, Eleni Louka, E. Ravza Gür, Nawshad Hayder, William E. Pierceall, Anjan Thakurta, Anita K. Gandhi, Patrick R Hagner, Jim Hughes, Adam J Mead
Journal: Blood
Blood (2023) 142 (Supplement 1): 935.
https://doi.org/10.1182/blood-2023-182041
Published: 2023
Journal Articles

Suppression of Myeloid Cell-Derived Proinflammatory Cytokines with Celmod Agents: Implications for CRS with T-Cell Engagers (TCEs)

Danny V Jeyaraju, Maryam Alapa, Aimee O'Donohue, Ross La Motte-Mohs, Isaac W. Boss, Patrick Hagner, Michael Pourdehnad, Michael R. Burgess, William E. Pierceall, Anjan Thakurta
Journal: Blood
Blood (2022) 140 (Supplement 1): 7070–7071.
https://doi.org/10.1182/blood-2022-157927
Published: 2022
Journal Articles

Large-Scale Mass Cytometry Reveals Significant Activation of Innate and Adaptive Immunity in Bone Marrow Tumor Microenvironment of Iberdomide-Treated Myeloma Patients

Oliver Van Oekelen, Michael Amatangelo, Manman Guo, Bhaskar Upadhyaya, Geoffrey Kelly, Manishkumar Patel, Seunghee Kim-Schulze, Alessandro Lagana, Sarah Gooding, Sundar Jagannath, William E. Pierceall, Udo Oppermann, Samir Parekh, Anjan Thakurta
Journal: Blood
Blood (2021) 138 (Supplement 1): 730.
https://doi.org/10.1182/blood-2021-151542
Published: 2021
Journal Articles

Loss of COP9 Signalosome Gene-Containing 2q Region Is Associated with Lenalidomide and Pomalidomide Resistance in Myeloma Patients

Sarah Gooding, Naser Ansari-Pour, Mohammad H Kazeroun, Kubra Karagoz, Mirian Angulo Salazar, Evelyn Fitzsimons, Maria Ortiz Estevez, Fadi Towfic, Erin Flynt, William E. Pierceall, Kwee Yong, Paresh Vyas, Anjan Thakurta
Journal: Blood
Blood (2021) 138 (Supplement 1): 458.
https://doi.org/10.1182/blood-2021-150166
Published: 2021
Journal Articles

Multidimensional Single Cell Analysis Shows Increased T/NK Cell Subsets in Both Blood and Bone Marrow of Iberdomide (CC-220) Treated Relapsed/Refractory Multiple Myeloma Patients

Michael Amatangelo, Oliver Van Oekelen, MD MSc, Adeeb H Rahman, PhD, Alessandro Lagana, PhD, Sarah Gooding, FRCPath,MRCP,MBBChir, Hervé Avet-Loiseau, MD PhD, Udo Oppermann, PhD, William E Pierceall, PhD, Anjan Thakurta, Samir Parekh, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1775.
https://doi.org/10.1182/blood-2019-126146
Published: 2019
Journal Articles

Favorable Progression-Free Survival Associated with Immune Bio-Markers Modulated By Pomalidomide in Relapsed/Refractory Multiple Myeloma: An Analysis of Phase III Study

Rao Prabhala, PhD, Mehmet Kemal Samur, PhD, Srikanth Talluri, PhD, Megan Stekla, BS, Chaitanya Yenumula, MD, Michael A Lopez, Sanika Derebail, Lakshmi B. Potluri, Angela Wang, Aishwarya Katiki, Sahan D. Vangala, Eric Haas, Michael J Buonopane, BS, Alexander T Heubeck, BS, Mariateresa Fulciniti, PhD, Raphael Szalat, MD, Suzan Lazo-Kallanian, BS, Kevin Hong, Teresa Peluso, John Daley, PhD, Tsvetan Biyukov, MD, Albert Oriol, William E. Pierceall, Paul G. Richardson, MD, Kenneth C. Anderson, MD, Anjan Thakurta, Hervé Avet-Loiseau, MD PhD, Nikhil C. Munshi, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1784.
https://doi.org/10.1182/blood-2019-131257
Published: 2019
Journal Articles

Prognostic Molecular Stratification in Relapsed/Refractory Multiple Myeloma - Results of the Pomalidomide Mukseven (NCT02406222) Biomarker Trial

James Croft, MBBS, BSc, Andrew Hall, Amy L Sherborne, PhD, Katrina Walker, Sidra Ellis, Kim Sharp, Amy Price, Charlotte Pawlyn, BA,PhDMBBChir,MRCP,FRCPath, Louise Flanagan, PhD, Mamta Garg, MD FRCP, FRCPath, Suzana Couto, Maria Wang, Kevin Boyd, MB BS, BSc, MRCP, FRCPath, PhD, William E Pierceall, PhD, Anjan Thakurta, Gordon Cook, Sarah R Brown, PhD MSc, BSc, Martin F. Kaiser
Journal: Blood
Blood (2019) 134 (Supplement_1): 4327.
https://doi.org/10.1182/blood-2019-123640
Published: 2019
Journal Articles

Translational and Clinical Evidence of a Differentiated Profile for the Novel CELMoD, Iberdomide (CC-220)

Sagar Lonial, Michael Amatangelo, Rakesh Popat, Monique C. Minnema, Jeffrey A. Zonder, Jeremy Larsen, Albert Oriol Rocafiguera, Erica L. Campagnaro, MD, Paula Rodriguez Otero, Ashraf Z. Badros, David S. Siegel, Sundar Jagannath, Sara Bringhen, Mercedes Gironella, Martin F. Kaiser, Gordon Cook, Barbara Gamberi, Pieter Sonneveld, Tuong Vi Nguyen, Min S. Chen, Trevor Homan, Chad C. Bjorklund, Maria Wang, William E. Pierceall, Amine Bensmaine, Anjan Thakurta, Teresa Peluso, Niels W. C. J. Van De Donk
Journal: Blood
Blood (2019) 134 (Supplement_1): 3119.
https://doi.org/10.1182/blood-2019-124298
Published: 2019
Journal Articles

Immune Profiling of Relapsed or Refractory Multiple Myeloma Patients Treated with Pomalidomide and Low-Dose Dexamethasone in Combination with Daratumumab

William E. Pierceall, Nizar Bahlis, MD, David S Siegel, MD PhD, Gary J. Schiller, MD, Christy J. Samaras, DO, Michael Sebag, MD PhD, Jesus G. Berdeja, MD, Siddhartha Ganguly, MD, Jeffrey V Matous, MD, Kevin Song, MD, Christopher S. Seet, MD, Giampaolo Talamo, Shanti Srinivas, Mirelis Acosta-Rivera, Michael Bar, Donald P. Quick, MD, Bertrand Anz, Gustavo Fonseca, Donna Reece, Weiyuan Chung, Natalya Serbina, Faiza Zafar, MPAS, Amit Agarwal, MD PhD, Anjan Thakurta, PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 2012.
https://doi.org/10.1182/blood-2018-99-111554
Published: 2018
Journal Articles

Cyclophosphamide Exerts Significant Immunomodulatory Function in Myeloma Patients Treated with Pomalidomide and Dexamethasone

James Croft, BSc, MBBS, MRCP, Andrew Hall, Katrina Walker, Amy L Sherborne, PhD, Kevin Boyd, Mamta Garg, Charlotte Pawlyn, BA, PhD MBBChir, MRCP, FRCPath, Debbie Sherratt, Sadie Reed, PhD, William E Pierceall, Gordon Cook, Anjan Thakurta, PhD, Sarah R Brown, PhD MSc, BSc, Martin Kaiser, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 4482.
https://doi.org/10.1182/blood-2018-99-111823
Published: 2018
Journal Articles

Single Cell Analysis of Acquired Pomalidomide-Resistance in Multiple Myeloma Cell Lines Reveals Distinct Subclonal Cereblon Mutations and Gene Expression Heterogeneity

Sarah Gooding, Chad C. Bjorklund, Michael Amatangelo, Yan Ren, Mathieu Marella, Suzana Couto, Christopher Park, Sneh Lata, Reshma Nibhani, Fadi Towfic, PhD, Udo Oppermann, Karthik Ramasamy, William E. Pierceall, Paresh Vyas, Anjan Thakurta, PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 2648.
https://doi.org/10.1182/blood-2018-99-112644
Published: 2018
Journal Articles

Modeling Tumor Microenvironment Interactions of Imid Sensitive and Resistant Cells in 3D Organotypic Culture Models

Aarif Ahsan, PhD, Danny Jeyaraju, Kamlesh Bisht, Patrick R. Hagner, PhD, Chad C. Bjorklund, William E Pierceall, Anjan Thakurta, PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 5622.
https://doi.org/10.1182/blood-2018-99-118885
Published: 2018
Journal Articles

Clinical BET Inhibitor RG6146 Demonstrates Potent and on-Target Activity in Pre-Clinical Models of Hematological Malignancy and Combines with Anti-CD20 and BCL-2 Inhibition to Provide Superior Efficacy

Astrid Rueflibrasse, PhD, Thomas Friess, PhD, Stephanie Lechner, Lisa Wellinger, Jurriaan Brouwer, William E. Pierceall, PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 2071.
https://doi.org/10.1182/blood.V130.Suppl_1.2071.2071
Published: 2017
Journal Articles

Minimal Residual Disease (MRD) Assessment By Multiparametric Flow Cytometry Is Prognostic for Progression-Free Survival in Phase 1/1b Relapsed/Refractory Acute Myeloid Leukemia (AML) Patients Treated with Idasanutlin MDM2 Antagonist

Benjamin Lanza, Giovanni Martinelli, Karen W.L. Yee, MD, Lori Jukofsky, Bernhard Reis, PhD, Steven Blotner, PhD, Mark W. Drummond, PhDMD, Norbert Vey, MD PhD, Karen Seiter, MD, Michael J. Dickinson, MBBS, FRACP, FRCPA, Kevin R. Kelly, MD PhD, Margaret Kasner, MD, Michel Theron, PhD, Jeffrey M. Venstrom, Steven Middleton, PhD, Lin-Chi Chen, MD PhD, Nelson Kinnersley, Gwen Nichols, MD, William E. Pierceall, PhD
Journal: Blood
Blood (2016) 128 (22): 2843.
https://doi.org/10.1182/blood.V128.22.2843.2843
Published: 2016
Journal Articles

Clinical Response to Idasanutlin (RG7388) in Acute Myeloid Leukemia Patients Is Associated with Pre-Treatment MDM2 Protein Expression in Leukemic Blasts and Leukemic Stem Cells

Bernhard Reis, PhD, Lori Jukofsky, Gong Chen, PhD, Giovanni Martinelli, Hua Zhong, PhD, Venus So, PhD, Michael J. Dickinson, MBBS, FRACP, FRCPA, Mark W. Drummond, PhDMD, Sarit E. Assouline, MDMSc, Maneja Hashemyan, Michel Theron, PhD, Steven Blotner, PhD, Je-Hwan Lee, MD PhD, Margaret Kasner, MD, Sung-Soo Yoon, Ruediger Rueger, MD, Karen Seiter, MD, Steven Middleton, PhD, Kevin R. Kelly, MD, PhD, Norbert Vey, Karen W.L. Yee, MD, Gwen Nichols, MD, Lin-Chi Chen, MD PhD, William E. Pierceall, PhD
Journal: Blood
Blood (2015) 126 (23): 2580.
https://doi.org/10.1182/blood.V126.23.2580.2580
Published: 2015
Journal Articles

Phase 1/1b Study of RG7388, a Potent MDM2 Antagonist, in Acute Myelogenous Leukemia (AML) Patients (Pts)

Karen Yee, MD, Giovanni Martinelli, MD, Norbert Vey, MDPhD, Michael J. Dickinson, MBBS, FRACP, FRCPA, Karen Seiter, MD, Sarit Assouline, MD MSc, Mark Drummond, MD PhD, Sung-Soo Yoon, MDPhD, Margaret Kasner, MD, Je-Hwan Lee, MD PhD, Kevin R. Kelly, MD PhD, Steven Blotner, PhD, Brian Higgins, Steven Middleton, PhD, Gwen Nichols, MD, Gong Chen, PhD, Hua Zhong, PhD, William E. Pierceall, PhD, Jianguo Zhi, PhD, Lin-Chi Chen, MD PhD
Journal: Blood
Blood (2014) 124 (21): 116.
https://doi.org/10.1182/blood.V124.21.116.116
Published: 2014
Journal Articles

Mcl-1 Dependence Predicts Response To Vorinostat and Gemtuzumab Ozogamicin In Acute Myeloid Leukemia

William E. Pierceall, PhD, Ryan Lena, BS, Bruno C. Medeiros, MD, Elihu H. Estey, MD, Noel Blake, B.S., Michael Elaschoff, Ph.D., Michael Cardone, PhD, Roland B. Walter, MD, PhD
Journal: Blood
Blood (2013) 122 (21): 1305.
https://doi.org/10.1182/blood.V122.21.1305.1305
Published: 2013
Journal Articles

BH3 Profiling As Predictor Of 5-Azacytidine and Decitabine Clinical Responses

Raoul Tibes, MD, PhD, Steven M. Kornblau, MD, William E. Pierceall, PhD, Ryan Lena, BS, Yi Hua Qiu, MD, Michael Cardone, PhD, Leena Chaudhuri, PhD, Veena Fauble, MD, Michael Elashoff, Noel Blake, B.S., Ruben A. Mesa, MD, James M Bogenberger, PhD
Journal: Blood
Blood (2013) 122 (21): 603.
https://doi.org/10.1182/blood.V122.21.603.603
Published: 2013
Journal Articles

BH3 Profiling Predicts 5-Azacytidine Response in Malignant Myeloid Cells

James M Bogenberger, PhD, William E. Pierceall, PhD, Ryan Lena, BS, Reinhold Munker, MD, Kaoru Tohyama, MD, PhD, Lisa Sproat, MD, MSW, Pierre Noel, MD, Jose F. Leis, MD, PhD, James L Slack, MD, Ruben A. Mesa, Michael Cardone, PhD, Raoul Tibes, MD, PhD
Journal: Blood
Blood (2012) 120 (21): 1432.
https://doi.org/10.1182/blood.V120.21.1432.1432
Published: 2012